Back
Green Plains 10K Form
Sell
40
GPRE
Green Plains
Last Price:
10.83
Seasonality Move:
3.38%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-03 | 10Q | GPRE/Green Plains Quarterly |
2023-10-31 | 10Q | GPRE/Green Plains Quarterly |
2023-08-04 | 10Q | GPRE/Green Plains Quarterly |
2023-05-04 | 10Q | GPRE/Green Plains Quarterly |
2022-11-03 | 10Q | GPRE/Green Plains Quarterly |
2022-08-02 | 10Q | GPRE/Green Plains Quarterly |
Receive GPRE News And Ratings
See the #1 stock for the next 7 days that we like better than GPRE
GPRE Financial Statistics
Sales & Book Value
Annual Sales: | $3.3B |
---|---|
Cash Flow: | $34.38M |
Price / Cash Flow: | 67.27 |
Annual Sales: | $14.32 |
Price / Book: | 0.78 |
Profitability
EPS (TTM): | -0.38000 |
---|---|
Net Income (TTM): | $-20.33M |
Gross Margin: | $191.91M |
Return on Equity: | -2.17% |
Return on Assets: | -1.1% |
Green Plains Earnings Forecast
Key Green Plains Financial Ratios
- The Gross Profit Margin over the past 18 years for GPRE is 5.82%.
- The Selling, General & Administrative Expenses for GPRE have been equal to 4.05% of Gross Profit Margin.
- The Research & Development expenses have been 0.00% of Revenue.
- The Interest Expense is -40.37% of Operating Income.
- The Net Earning history of GPRE is -2.83% of Total Revenues.
- Per Share Earnings over the last 19 years have been positive in 11 years.
Green Plains Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Oil, Gas & Consumable Fuels |
Sector: | Energy |
Current Symbol: | GPRE |
CUSIP: | 393222 |
Website: | gpreinc.com |
Debt
Debt-to-Equity Ratio: | 0.59 |
---|---|
Current Ratio: | 1.78 |
Quick Ratio: | 0.96 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 16 |
GPRE Technical Analysis vs Fundamental Analysis
Sell
40
Green Plains (GPRE)
is a Sell
Is Green Plains a Buy or a Sell?
-
Green Plains stock is rated a Sell
The current Green Plains [GPRE] share price is $10.81. The Score for GPRE is 40, which is 20% below its historic median score of 50, and infers higher risk than normal.